Molecular targeting of growth factor receptor-bound 2 (Grb2) as an anti-cancer strategy

Anti-Cancer Drugs

Volumn 17, Issue 1, 2006, Pages 13-20

  Dharmawardana, Pathirage G ^a   Peruzzi, Benedetta ^a   Giubellino, Alessio ^a   Burke Jr , Terrence R ^a   Bottaro, Donald P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; Cancer; Cell motility; Grb2; Growth factor receptor bound 2; Metastasis

Indexed keywords

CELL SURFACE RECEPTOR; GROWTH FACTOR RECEPTOR; GROWTH FACTOR RECEPTOR BOUND 2; RAS PROTEIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INVASION; CARCINOGENESIS; CELL MOTILITY; METASTASIS; PRIORITY JOURNAL; PROTEIN STRUCTURE; SRC HOMOLOGY DOMAIN; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; GRB2 ADAPTOR PROTEIN; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 33646104191     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000185180.72604.ac     Document Type: Article

References (73)

1. Clark SG, Stern MJ, Horvitz HR. C. elegans cell-signalling gene sem-5 encodes a protein with SH2 and SH3 domains. Nature 1992; 356: 340-344.
2. Lowenstein EJ, Daly RJ, Batzer AG, Li W, Margolis B, Lammers R, et al. The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell 1992; 70:431-442.
3. Bochmann H, Gehrisch S, Jaross W. The gene structure of the human growth factor bound protein GRB2. Genomics 1999; 56:203-207.
4. Olivier JP, Raabe T, Henkemeyer M, Dickson B, Mbamalu G, Margolis B, et al. A Drosophila SH2-SH3 adaptor protein implicated in coupling the sevenless tyrosine kinase to an activator of Ras guanine nucleotide exchange, Sos. Cell 1993; 73:179-191.
5. Simon MA, Dodson GS, Rubin GM. An SH3-SH2-SH3 protein is required for p21Ras1 activation and binds to sevenless and Sos proteins in vitro. Cell 1993; 73:169-177.
6. Stern MJ, Marengere LE, Daly RJ, Lowenstein EJ, Kokel M, Batzer A, et al. The human GRB2 and Drosophila Drk genes can functionally replace the Caenorhabditis elegans cell signaling gene sem-5. Mol Biol Cell 1993; 4:1175-1188.
7. Cheng AM, Saxton TM, Sakai R, Kulkarni S, Mbamalu G, Vogel W, et al. Mammalian Grb2 regulates multiple steps in embryonic development and malignant transformation. Cell 1998; 95:793-803.
8. Gong Q, Cheng AM, Akk AM, Alberola-Ila J, Gong G, Pawson T, et al. Disruption of T cell signaling networks and development by Grb2 haploid insufficiency. Nat Immunol 2001; 2:29-36.
9. Zhang S, Weinheimer C, Courtois M, Kovacs A, Zhang CE, Cheng AM, et al. The role of the Grb2-p38 MAPK signaling pathway in cardiac hypertrophy and fibrosis. J Clin Invest 2003; 111:833-841.
10. gag-crk, to a broad range of phosphotyrosine-containing proteins. Science 1990; 248:1537-1539.
11. Cantley LC, Auger KR, Carpenter C, Duckworth B, Graziani A, Kapeller R, et al. Oncogenes and signal transduction. Cell 1991; 64:281-302.
12. Songyang Z, Cantley LC. Recognition and specificity in protein tyrosine kinase-mediated signalling. Trends Biochem Sci 1995; 20:470-475.
13. Pawson T, Saxton TM. Signaling networks - do all roads lead to the same genes? Cell 1999; 97:675-678.
14. Yamauchi T, Ueki K, Tobe K, Tamemoto H, Sekine N, Wada M, et al. Growth hormone-induced tyrosine phosphorylation of EGF receptor as an essential element leading to MAP kinase activation and gene expression. Endocr J 1998; 45 (Suppl):27-31.
15. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003; 4:915-925.
16. Zhang W, Samelson LE. The role of membrane-associated adaptors in T cell receptor signalling. Semin Immunol 2000; 12:35-41.
17. Tybulewicz VL. Vav-family proteins in T-cell signalling. Curr Opin Immunol 2005; 17:267-274.
18. Carlier MF, Nioche P, Broutin-L'Hermite I, Boujemaa R, Le Clainche C, Egile C, et al. GRB2 links signaling to actin assembly by enhancing interaction of neural Wiskott-Aldrich syndrome protein (N-WASp) with actin-related protein (ARP2/3) complex. J Biol Chem 2000; 275:21946-21952.
19. Carlier MF, Le Clainche C, Wiesner S, Pantaloni D. Actin-based motility: from molecules to movement. BioEssays 2003; 25:336-345.
20. Scaplehorn N, Holmstrom A, Moreau V, Frischknecht F, Reckmann I, Way M. Grb2 and Nck act cooperatively to promote actin-based motility of vaccinia virus. Curr Biol 2002; 12:740-745.
21. Ferrara N. The role of VEGF in the regulation of physiological and pathological angiogenesis. Exs 2005; 209-231.
22. Tammela T, Enholm B, Alitalo K, Paavonen K. The biology of vascular endothelial growth factors. Cardiovasc Res 2005; 65:550-563.
23. Stein E, Cerretti DP, Daniel TO. Ligand activation of ELK receptor tyrosine kinase promotes its association with Grb10 and Grb2 in vascular endothelial cells. J Biol Chem 1996; 271:23588-23593.
24. Jones N, Master Z, Jones J, Bouchard D, Gunji Y, Sasaki H, et al. Identification of Tek/Tie2 binding partners. Binding to a multifunctional docking site mediates cell survival and migration. J Biol Chem 1999; 274:30896-30905.
25. Rosen EM, Lamszus K, Laterra J, Polverini PJ, Rubin JS, Goldberg ID. HGF/SF in angiogenesis. Ciba Found Symp 1997; 212:215-226.
26. Atabey N, Gao Y, Yao ZJ, Breckenridge D, Soon L, Soriano JV, et al. Potent blockade of hepatocyte growth factor-stimulated cell motility, matrix invasion and branching morphogenesis by antagonists of Grb2 Src homology 2 domain interactions. J Biol Chem 2001; 276:14308-14314.
27. Soriano JV, Liu N, Gao Y, Yao ZJ, Ishibashi T, Underhill C, et al. Inhibition of angiogenesis by growth factor receptor bound protein 2-Src homology 2 domain bound antagonists. Mol Cancer Ther 2004; 3:1289-1299.
28. Bornfeldt KE, Raines EW, Graves LM, Skinner MP, Krebs EG, Ross R. Platelet-derived growth factor. Distinct signal transduction pathways associated with migration versus proliferation. Ann NY Acad Sci 1995; 766:416-430.
29. Beckmann MP, Cerretti DP, Baum P, Vanden Bos T, James L, Farrah T, et al. Molecular characterization of a family of ligands for Eph-related tyrosine kinase receptors. EMBO J 1994; 13:3757-3762.
30. Furge KA, Zhang YW, Vande Woude GF. Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene 2000; 19: 5582-5589.
31. Linehan WM, Vasselli J, Srinivasan R, Walther MM, Merino M, Choyke P, et al. Genetic basis of cancer of the kidney: disease-specific approaches to therapy. Clin Cancer Res 2004; 10:6282S-6289S.
32. Dharmawardana PG, Giubellino A, Bottaro DP. Hereditary papillary renal carcinoma type I. Curr Mol Med 2004; 4:855-868.
33. Castagnino P, Soriano JV, Montesano R, Bottaro DP. Induction of tissue inhibitor of metalloproteinases-3 is a delayed early cellular response to hepatocyte growth factor. Oncogene 1998; 17:481-492.
34. Corso S, Comoglio PM, Giordano S. Cancer therapy: can the challenge be MET? Trends Mol Med 2005; 11:284-292.
35. Fixman ED, Fournier TM, Kamikura DM, Naujokas MA, Park M. Pathways downstream of Shc and Grb2 are required for cell transformation by the Tpr-Met oncoprotein. J Biol Chem 1996; 271:13116-13122.
36. Ponzetto C, Zhen Z, Audero E, Maina F, Bardelli A, Basile ML, et al. Specific uncoupling of GRB2 from the Met receptor. Differential effects on transformation and motility. J Biol Chem 1996; 271:14119-14123.
37. Giordano S, Bardelli A, Zhen Z, Menard S, Ponzetto C, Comoglio PM. A point mutation in the MET oncogene abrogates metastasis without affecting transformation. Proc Natl Acad Sci USA 1997; 94:13868-13872.
38. Bardelli A, Basile ML, Audero E, Giordano S, Wennstrom S, Menard S, et al. Concomitant activation of pathways downstream of Grb2 and PI 3-kinase is required for MET-mediated metastasis. Oncogene 1999; 18:1139-1146.
39. Saucier C, Papavasiliou V, Palazzo A, Naujokas MA, Kremer R, Park M. Use of signal specific receptor tyrosine kinase oncoproteins reveals that pathways downstream from Grb2 or Shc are sufficient for cell transformation and metastasis. Oncogene 2002; 21:1800-1811.
40. Pendergast AM, Quilliam LA, Cripe LD, Bassing CH, Dai Z, Li N, et al. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 1993; 75:175-185.
41. Gishizky ML, Cortez D, Pendergast AM. Mutant forms of growth factor-binding protein-2 reverse BCR-ABL-induced transformation. Proc Natl Acad Sci USA 1995; 92:10889-10893.
42. Janes PW, Daly RJ, deFazio A, Sutherland RL. Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2. Oncogene 1994; 9:3601-3608.
43. Yip SS, Crew AJ, Gee JM, Hui R, Blamey RW, Robertson JF, et al. Up-regulation of the protein tyrosine phosphatase SHP-1 in human breast cancer and correlation with GRB2 expression. Int J Cancer 2000; 88: 363-368.
44. Zang XP, Siwak DR, Nguyen TX, Tari AM, Pento JT. KGF-induced motility of breast cancer cells is dependent on Grb2 and Erk1,2. Clin Exp Metastasis 2004; 21:437-443.
45. Watanabe T, Shinohara N, Moriya K, Sazawa A, Kobayashi Y, Ogiso Y, et al. Significance of the Grb2 and son of sevenless (Sos) proteins in human bladder cancer cell lines. IUBMB Life 2000; 49:317-320.
46. Misra UK, Pizzo SV. Potentiation of signal transduction mitogenesis and cellular proliferation upon binding of receptor-recognized forms of alpha2-macroglobulin to 1-LN prostate cancer cells. Cell Signal 2004; 16: 487-496.
47. Mayer BJ. SH3 domains: complexity in moderation. J Cell Sci 2001; 114:1253-1263.
48. Buday L. Membrane-targeting of signalling molecules by SH2/SH3 domain-containing adaptor proteins. Biochim Biophys Acta 1999; 1422:187-204.
49. Garbay C, Liu WQ, Vidal M, Roques BP. Inhibitors of Ras signal transduction as antitumor agents. Biochem Pharmacol 2000; 60: 1165-1169.
50. Vidal M, Liu WQ, Lenoir C, Salzmann J, Gresh N, Garbay C. Design of peptoid analogue dimers and measure of their affinity for Grb2 SH3 domains. Biochemistry 2004; 43:7336-7344.
51. Machida K, Mayer BJ. The SH2 domain: versatile signaling module and pharmaceutical target. Biochim Biophys Acta 2005; 1747:1-25.
52. Rahuel J, Gay B, Erdmann D, Strauss A, Garcia-Echeverria C, Furet P, et al. Structural basis for specificity of Grb2-SH2 revealed by a novel ligand binding mode. Nat Struct Biol 1996; 3:586-589.
53. Burke TR Jr. Development of Grb2 SH2 domain signaling antagonists: a potential new class of antiproliferative agents. Int J Peptide Res Ther 2005; in press.
54. Burke TR Jr, Smyth MS, Otaka A, Nomizu M, Roller PP, Wolf G, et al. Nonhydrolyzable phosphotyrosyl mimetics for the preparation of phosphatase-resistant SH2 domain inhibitors. Biochemistry 1994; 33:6490-6494.
55. Burke TR Jr, Luo J, Yao ZJ, Gao Y, Zhao H, Milne GW, et al. Monocarboxylic-based phosphotyrosyl mimetics in the design of GRB2 SH2 domain inhibitors. Bioorg Med Chem Lett 1999; 9:347-352.
56. Gao Y, Luo J, Yao ZJ, Guo R, Zou H, Kelley J, et al. Inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands. 2.4-(2-Malonyl) phenylalanine as a potent phosphotyrosyl mimetic. J Med Chem 2000; 43:911-920.
57. Gao Y, Wu L, Luo JH, Guo R, Yang D, Zhang ZY, et al. Examination of novel non-phosphorus-containing phosphotyrosyl mimetics against protein-tyrosine phosphatase-1B and demonstration of differential affinities toward Grb2 SH2 domains. Bioorg Med Chem Lett 2000; 10:923-927.
58. Schoepfer J, Gay B, Caravatti G, Garcia-Echeverria C, Fretz H, Rahuel J, et al. Structure-based design of peptidomimetic ligands of the Grb2-SH2 domain. Bioorg Med Chem Lett 1998; 8:2865-2870.
59. Rahuel J, Garcia-Echeverria C, Furet P, Strauss A, Caravatti G, Fretz H, et al. Structural basis for the high affinity of amino-aromatic SH2 phosphopeptide ligands. J Mol Biol 1998; 279:1013-1022.
60. 2. J Med Chem 1998; 41:1741-1744.
61. Oligino L, Lung FD, Sastry L, Bigelow J, Cao T, Curran M, et al. Nonphosphorylated peptide ligands for the Grb2 Src homology 2 domain. J Biol Chem 1997; 272:29046-29052.
62. Furet P, Gay B, Caravatti G, Garcia-Echeverria C, Rahuel J, Schoepfer J, et al. Structure-based design and synthesis of high affinity tripeptide ligands of the Grb2-SH2 domain. J Med Chem 1998; 41:3442-3449.
63. Rojas M, Yao S, Lin YZ. Controlling epidermal growth factor (EGF)-stimulated Ras activation in intact cells by a cell-permeable peptide mimicking phosphorylated EGF receptor. J Biol Chem 1996; 271: 27456-27461.
64. Williams EJ, Dunican DJ, Green PJ, Howell FV, Derossi D, Walsh FS, Doherty P. Selective inhibition of growth factor-stimulated mitogenesis by a cell-permeable Grb2-binding peptide. J Biol Chem 1997; 272:22349-22354.
65. Gay B, Suarez S, Caravatti G, Furet P, Meyer T, Schoepfer J. Selective GRB2 SH2 Inhibitors as anti-Ras therapy. Int J Cancer 1999; 83:235-241.
66. Gay B, Suarez S, Weber C, Rahuel J, Fabbro D, Furet P, et al. Effect of potent and selective inhibitors of the Grb2 SH2 domain on cell motility. J Biol Chem 1999; 274:23311-23315.
67. Yao ZJ, King CR, Cao T, Kelley J, Milne GW, Voigt JH, et al. Potent inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands. J Med Chem 1999; 42:25-35.
68. Mousa SA, Mousa AS. Angiogenesis inhibitors: current and future directions. Curr Pharm Des 2004; 10:1-9.
69. Sawyer TK, Bohacek RS, Dalgarno DC, Eyermann CJ, Kawahata N, Metcalf CA III, et al. SRC homology-2 inhibitors: peptidomimetic and nonpeptide. Mini Rev Med Chem 2002; 2:475-488.
70. Oishi S, Karki RG, Shi ZD, Worthy KM, Bindu L, Chertov O, et al. Evaluation of macrocyclic Grb2 SH2 domain-binding peptide mimetics prepared by ring-closing metathesis of C-terminal allylglycines with an N-terminal beta-vinyl-substituted phosphotyrosyl mimetic. Bioorg Med Chem 2005; 13:2431-2438.
71. Kang SU, Shi ZD, Worthy KM, Bindu LK, Dharmawardana PG, Choyke SJ, et al. Examination of phosphoryl-mimicking functionalities within a macrocyclic Grb2 SH2 domain-binding platform. J Med Chem 2005; 48:3945-3948.
72. Shi ZD, Karki RG, Oishi S, Worthy KM, Bindu LK, Dharmawardana PG, et al. Utilization of a nitrobenzoxadiazole (NBD) fluorophore in the design of a Grb2 SH2 domain-binding peptide mimetic. Bioorg Med Chem Lett 2005; 15:1385-1388.
73. Shi ZD, Liu H, Zhang M, Worthy KM, Bindu L, Yang D, et al. Synthesis of a C-terminally biotinylated macrocyclic peptide mimetic exhibiting high Grb2 SH2 domain-binding affinity. Bioorg Med Chem 2005; 13:4200-4208.